Annals of Oncology Advance Access originally published online on July 12, 2005
Annals of Oncology 2005 16(9):1425-1433; doi:10.1093/annonc/mdi279
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Review |
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
1 Department of Dermatology, University Hospital, Katholieke Universiteit Leuven 2 Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
* Correspondence to: Prof. Dr E. Van Cutsem, Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Tel: +32-16-344-218; Fax: +32-16-344-419; Email: eric.vancutsem{at}uz.kuleuven.ac.be
The last few years, new therapies targeting the epidermal growth factor receptor (EGFR) have shown their efficacy in the treatment of several types of cancer. Monoclonal antibodies against the EGFR (e.g. cetuximab, panitumumab) or EGFR tyrosine kinase inhibitors (e.g. gefitinib, erlotinib) are generally well tolerated and do not have the severe systemic side-effects usually seen with cytotoxic drugs. A considerable number of patients treated with these EGFR inhibitors, however, develop dermatological side-effects, most frequently an acneiform eruption but also xerosis, eczema, fissures, telangiectasia, hyperpigmentation, hair changes and paronychia with pyogenic granuloma. These skin effects appear to be mechanism-based linked to the inhibition of EGFR action but the exact pathophysiology remains elusive. Left untreated these dermatological side-effects could represent a threat to patient compliance. Therefore effective management is mandatory. Mild cases of acneiform eruption respond well to topical anti-inflammatory acne therapy, whereas tetracyclines are needed to treat moderate to severe cases. This review outlines the broad spectrum of cutaneous side-effects of EGFR inhibitors, discusses possible underlying mechanisms and provides practical guidelines for the management based on literature data and on personal experience.
Key words: acneiform eruption, cetuximab, epidermal growth factor receptor, erlotinib, gefitinib
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. H. Tan and A. Chan Evidence-Based Treatment Options for the Management of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors Ann. Pharmacother., October 1, 2009; 43(10): 1658 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Surguladze, D. Deevi, N. Claros, E. Corcoran, S. Wang, M. J. Plym, Y. Wu, J. Doody, D. J. Mauro, L. Witte, et al. Tumor Necrosis Factor-{alpha} and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice Cancer Res., July 15, 2009; 69(14): 5643 - 5647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sans, T. Jouary, T. Hubiche, D. Smith, B. Milpied, and A. Taieb Baboon Syndrome Induced by Cetuximab Arch Dermatol, February 1, 2008; 144(2): 272 - 274. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bernier, J Bonner, J. B. Vermorken, R.-J. Bensadoun, R. Dummer, J. Giralt, G. Kornek, A. Hartley, R. Mesia, C. Robert, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck Ann. Onc., January 1, 2008; 19(1): 142 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Tan, S. M. Steinberg, A. L. Parr, D. Nguyen, and S. X. Yang Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment Ann. Onc., January 1, 2008; 19(1): 185 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Folprecht, J. Tabernero, C.-H. Kohne, C. Zacharchuk, L. Paz-Ares, F. Rojo, S. Quinn, E. Casado, R. Salazar, R. Abbas, et al. Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer Clin. Cancer Res., January 1, 2008; 14(1): 215 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Scope, A. L. C. Agero, S. W. Dusza, P. L. Myskowski, J. A. Lieb, L. Saltz, N. E. Kemeny, and A. C. Halpern Randomized Double-Blind Trial of Prophylactic Oral Minocycline and Topical Tazarotene for Cetuximab-Associated Acne-Like Eruption J. Clin. Oncol., December 1, 2007; 25(34): 5390 - 5396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers Oncologist, December 1, 2007; 12(12): 1443 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Boeck, A Wollenberg, and V Heinemann Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib Ann. Onc., September 1, 2007; 18(9): 1582 - 1583. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Bauman, K. D. Eaton, and R. G. Martins Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab Arch Dermatol, July 1, 2007; 143(7): 889 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P. J. Cagnoni Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies Clin. Cancer Res., July 1, 2007; 13(13): 3913 - 3921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Cutsem, C. Verslype, and P. A. Grusenmeyer Lessons Learned in the Management of Advanced Pancreatic Cancer J. Clin. Oncol., May 20, 2007; 25(15): 1949 - 1952. [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer Adjuvant Treatment of Colorectal Cancer CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Lynch Jr., E. S. Kim, B. Eaby, J. Garey, D. P. West, and M. E. Lacouture Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management Oncologist, May 1, 2007; 12(5): 610 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E Saadeh and H S. Lee Panitumumab: A Fully Human Monoclonal Antibody with Activity in Metastatic Colorectal Cancer Ann. Pharmacother., April 1, 2007; 41(4): 606 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-Y. Tsai, C.-H. Yang, T.-t. Kuo, H.-S. Hong, and J. W.C. Chang Hand-Foot Syndrome and Seborrheic Dermatitis-Like Rash Induced by Sunitinib in a Patient With Advanced Renal Cell Carcinoma J. Clin. Oncol., December 20, 2006; 24(36): 5786 - 5788. [Full Text] [PDF]
|
|
|
|
|
|
E. Van Cutsem Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer Oncologist, October 1, 2006; 11(9): 1010 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. High Gefitinib: a cause of pyogenic granulomalike lesions of the nail. Arch Dermatol, July 1, 2006; 142(7): 939 - 939. [Full Text] [PDF]
|
|